---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-014338"
form_type: "8-K"
ticker: "CPHI"
cik: "0001106644"
company_name: "CHINA PHARMA HOLDINGS, INC."
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:30:54.781189+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# China Pharma Holdings acquires topiroxostat nanoemulsion patent for $8.82M in stock

## Summary
- Transfer price of $8.82M paid in 12.6M restricted shares at $0.70/share; closing by Feb 20, 2026.
- Transferor Xiaoyun Chen to provide technical services including R&D and registration.
- Transferor also entitled to 3% of net profit from product after commercial launch.
- Patent covers Topiroxostat Nanoemulsion and method; patent expires July 2036.

## SEC filing metadata
- accession: 0001213900-26-014338
- form_type: 8-K
- ticker: CPHI
- cik: 0001106644
- company_name: CHINA PHARMA HOLDINGS, INC.
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1106644/000121390026014338/0001213900-26-014338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1106644/000121390026014338/ea0276369-8k_china.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-014338
- JSON: https://secwatch.observer/filing/0001213900-26-014338.json
- Plain text: https://secwatch.observer/filing/0001213900-26-014338.txt

## Key facts
- Material Agreements
  CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Xiaoyun Chen valued at $8.82 million in common stock at $0.70 per share (effective 2026-02-05).
  - Action: entry
  - Agreement: license
  - Counterparty: Xiaoyun Chen
  - Value: $8.82 million in common stock at $0.70 per share
  - Effective: 2026-02-05
  source text: On February 5, 2026 (the "Signing Date"), Hainan Helpson Medical & Biotechnology Co., Ltd (" Helpson "), a wholly owned subsidiary of China Pharma Holdings, Inc. (the " Company "), entered into a Technology Transfer Agreement (the " Agreement ") with Xiaoyun Chen (the " Transferor ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1106644/000121390026014338/0001213900-26-014338-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.